Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

ABSTRACT:

Background

Influenza vaccine production capacity is still insufficient to meet global demand in case of a pandemic. To expand worldwide influenza vaccine production capacity, a solid and transferable egg-based influenza vaccine production process was established that is suitable for upscaling and technology transfer to vaccine manufacturers in low- and middle-income countries. As a proof-of-concept, the safety and immunogenicity of a pandemic whole inactivated virus (WIV) vaccine (H5N1) and a monovalent seasonal WIV vaccine (H3N2) were evaluated in a phase I clinical trial in adults.

Methods

Subjects were vaccinated with 2 doses of pandemic WIV vaccine (pWIV), or one dose of either seasonal WIV vaccine (sWIV) or a commercially available trivalent comparator vaccine followed

SUBMITTER: van Boxtel RA 

PROVIDER: S-EPMC4514258 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature